The role of alemtuzumab in the treatment of chronic lymphocytic leukemia (CLL) and the achievement of minimal residual disease negativity in relapsed/refractory CLL. Hematology Meeting Reports (formerly Haematologica Reports), [S. l.], v. 1, n. 2, 2009. DOI: 10.4081/hmr.v1i2.226. Disponível em: https://journals.pagepress.org/hmr/article/view/226. Acesso em: 20 jun. 2025.